FIMECS is Named One of “TOP10 BIOTECH STARTUPS IN APAC-2019” Companies
News release Download PDF
Kanagawa, Japan, 8 October 2019 – FIMECS, Inc. (“FIMECS”), a private biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it has been named by STARTUPCITY as one of “TOP10 BIOTECH STARTUPS IN APAC-2019” companies.
Please find FIMECS’ Start-up story in the following URL.
For more information:
About FIMECS, Inc.
FIMECS, Inc. is developing a new class of drugs based on targeted protein degradation for the currently ‘undruggable’ targets in immuno-oncology and oncology areas. The company became able to discover drug candidates for inducing the degradation of disease-relevant targeted proteins by integrating proprietary E3 ligase binders and RaPPIDS™ platform. This drug discovery platform will help providing drugs to the patients all over the world through various internal and collaboration projects.
About STARTUP CITY
# # #
FIMECS, Inc. Media and Investor Contact:
Yusuke Kohno, CFO and VP of Corporate Development
26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan